1-4 of 4
Pamela N. Munster
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors

Open Access
Christopher T. Chen, Vishesh Khanna, Shivaani Kummar, Raghad M. Abdul-Karim, David Sommerhalder, Anthony W. Tolcher, Naoto T. Ueno, Sarah Lindsey Davis, Douglas W. Orr, Erika Hamilton, Manish R. Patel, Alexander I. Spira, Shekeab Jauhari, Vaia Florou, Maureen Duff, Rongda Xu, Jian Wang, Shravani R. Barkund, Haiying Zhou, Aleksandr Pankov, Wayne Kong, Nadine S. Jahchan, Erica L. Jackson, Jessica D. Sun, Melissa R. Junttila, Pratik S. Multani, Anneleen Daemen, Edna Chow Maneval, Pamela N. Munster
Journal: Cancer Research Communications
Cancer Research Communications (2024) 4 (9): 2415–2426.
https://doi.org/10.1158/2767-9764.CRC-24-0115
Published: 13 September 2024
View articletitled, ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors
Open the PDF for ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170)

Open Access
Edward Maldonado, W. Kimryn Rathmell, Geoffrey I. Shapiro, Naoko Takebe, Jordi Rodon, Devalingam Mahalingam, Nikolaos A. Trikalinos, Arash R. Kalebasty, Mamta Parikh, Scott A. Boerner, Celene Balido, Gregor Krings, Timothy F. Burns, Emily K. Bergsland, Pamela N. Munster, Alan Ashworth, Patricia LoRusso, Rahul R. Aggarwal
Journal: Cancer Research Communications
Cancer Research Communications (2024) 4 (7): 1793–1801.
https://doi.org/10.1158/2767-9764.CRC-24-0213
Published: 23 July 2024
View articletitled, A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170)
Open the PDF for A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170) in another window
Includes: Supplementary data
Journal Articles

First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors

Open Access
Mark Yarchoan, John D. Powderly, Bruno R. Bastos, Thomas B. Karasic, Oxana V. Crysler, Pamela N. Munster, Meredith A. McKean, Leisha A. Emens, Yvonne M. Saenger, Yasser Ged, Robert Stagg, Steven Smith, Chan C. Whiting, Anne Moon, Peppi Prasit, Yonchu Jenkins, Nathan Standifer, Thomas W. Dubensky, Sam H. Whiting, Susanna V. Ulahannan
Journal: Cancer Research Communications
Cancer Research Communications (2024) 4 (4): 1100–1110.
https://doi.org/10.1158/2767-9764.CRC-24-0082
Published: 18 April 2024
View articletitled, First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
Open the PDF for First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies

Open Access
Erica S. Tsang, Rahul R. Aggarwal, Mallika S. Dhawan, Emily K. Bergsland, Edwin A. Alvarez, Susan Calabrese, Romain Pacaud, Jose Garcia, Delaire Fattah, Scott Thomas, Jennifer Grabowsky, Mark M. Moasser, Pamela N. Munster
Journal: Cancer Research Communications
Cancer Research Communications (2022) 2 (7): 570–576.
https://doi.org/10.1158/2767-9764.CRC-22-0028
Published: 01 July 2022
View articletitled, A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies
Open the PDF for A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies in another window
Includes: Supplementary data